Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: June 1997
To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.

Condition Intervention Phase
HIV Infections
Biological: HIV-1 Immunogen
Phase 3

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Regardless of Concomitant HIV Therapies

Resource links provided by NLM:

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 3000
Detailed Description:
Patients receive 10 units of HIV-1 immunogen in IFA or IFA alone every 12 weeks, then are followed for 104-148 weeks.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Concurrent Medication:


  • Antiretrovirals if on a stable dose for at least the past 3 months.

Patients must have:

  • HIV-1 infection with CD4 count 300-549 cells/mm3.
  • No AIDS-defining condition.
  • Been on a stable dose of antiretroviral for the past 3 months, if taking antiretrovirals.


  • KS is permitted if not requiring systemic therapy.

Prior Medication:


  • Prior antiretrovirals.

Exclusion Criteria

Concurrent Medication:


  • Systemic chemotherapy for KS.
  • Treatment for malignancy other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

Patients with the following prior conditions are excluded:

  • History of any illness that would interfere with study.
  • Acute infection requiring prescription therapy within the past month, other than genital herpes and oral or vaginal candidiasis.

Prior Medication:


  • Prior HIV-1 Immunogen. Unwilling to use effective safe sex practices. Active substance abuse.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002359

  Hide Study Locations
United States, Arizona
Phoenix Body Positive
Phoenix, Arizona, United States, 85016
United States, California
Ctr for Special Immunology
Irvine, California, United States, 92718
Jeffrey Goodman Special Care Clinic
Los Angeles, California, United States, 90028
Kraus Med Partners
Los Angeles, California, United States, 90036
Cedars Sinai Med Ctr
Los Angeles, California, United States, 90048
AIDS Community Research Consortium
Redwood City, California, United States, 94063
United States, District of Columbia
Whitman Walker Clinic Inc
Washington, District of Columbia, United States, 20009
Anderson Clinical Research
Washington, District of Columbia, United States, 20037
George Washington Univ Med Ctr
Washington, District of Columbia, United States, 20037
United States, Florida
North Broward Hosp District
Fort Lauderdale, Florida, United States, 33316
Ctr for Special Immunology
Miami Beach, Florida, United States, 33140
The Coleman Institute
North Miami, Florida, United States, 33179
Clinical Pharmacology Services
Tampa, Florida, United States, 33617
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30308
United States, Illinois
Rush Med Ctr
Chicago, Illinois, United States, 60612
Chicago AIDS Research Alliance
Chicago, Illinois, United States, 60657
Ctr for Special Immunology
Chicago, Illinois, United States, 60657
United States, Indiana
Community Hosp Indianapolis
Indianapolis, Indiana, United States, 46219
United States, Kansas
UKSM-W Med Practice Association
Wichita, Kansas, United States, 67214
United States, Kentucky
Univ of Kentucky / Division of ID Research
Lexington, Kentucky, United States, 40536
United States, Massachusetts
JSI Research and Training Institute
Boston, Massachusetts, United States, 02210
Community Research Initiative of New England
Brookline Village, Massachusetts, United States, 02445
Providence Mercy Hosp
Holyoke, Massachusetts, United States, 01040
United States, Michigan
Wayne State Univ / WSU / DMC HIV / AIDS Program
Detroit, Michigan, United States, 48201
Henry Ford Hosp / Infectious Diseases
Detroit, Michigan, United States, 48202
United States, Minnesota
Abbott Northwestern Hosp
Minneapolis, Minnesota, United States, 55407
United States, Missouri
Kansas City AIDS Research Consortium
Kansas City, Missouri, United States, 64111
Washington Univ / St Louis Connect Care
Saint Louis, Missouri, United States, 63108
United States, New York
Bronx Lebanon Hosp Ctr
Bronx, New York, United States, 10456
Anderson Clinical Research
New York, New York, United States, 10016
St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis
New York, New York, United States, 10019
Cornell Univ Med College
New York, New York, United States, 10021
Mount Sinai Med Ctr
New York, New York, United States, 10029
Dr Barbara Justice
New York, New York, United States, 10031
Community Health Network
Rochester, New York, United States, 14620
United States, North Carolina
Nalle Clinic
Charlotte, North Carolina, United States, 28207
United States, Ohio
Univ of Cincinnati Med Ctr / Holmes Division
Cincinnati, Ohio, United States, 45267
Ohio State Univ / Division of Infectious Disease
Columbus, Ohio, United States, 43210
United States, Oklahoma
Univ of Oklahoma
Oklahoma City, Oklahoma, United States, 73117
United States, Oregon
The Research and Education Group
Portland, Oregon, United States, 97210
United States, Pennsylvania
The Graduate Hosp
Philadelphia, Pennsylvania, United States, 19146
Anderson Clinical Research
Pittsburgh, Pennsylvania, United States, 15218
United States, Rhode Island
Mem Hosp of Rhode Island
Pawtucket, Rhode Island, United States, 02860
United States, South Carolina
Med Univ of South Carolina
Charleston, South Carolina, United States, 29425
United States, Tennessee
Vanderbilt Univ Med Ctr
Nashville, Tennessee, United States, 37212
United States, Texas
Metroplex Clinical Research Ctr
Dallas, Texas, United States, 75235
Univ of Texas Med Branch Ctr for Clinical Studies
Galveston, Texas, United States, 77555
ONCOL Med Associates / PA
Houston, Texas, United States, 77027
United States, Utah
Univ of Utah Med School / Clinical Trials Ctr
Salt Lake City, Utah, United States, 84108
United States, Virginia
Infectious Disease Physicians Inc
Annandale, Virginia, United States, 22003
Hampton Roads Med Specialists
Hampton, Virginia, United States, 23666
Eastern Virginia Med School
Norfolk, Virginia, United States, 23507
United States, Washington
Novum Inc
Seattle, Washington, United States, 98104
United States, Wisconsin
Wisconsin AIDS Research Consortium
Milwaukee, Wisconsin, United States, 53203
Sponsors and Collaborators
The Immune Response Corporation
  More Information

Publications: Identifier: NCT00002359     History of Changes
Other Study ID Numbers: 092
Study First Received: November 2, 1999
Last Updated: June 23, 2005

Keywords provided by NIH AIDS Clinical Trials Information Service:
Vaccines, Synthetic
Viral Vaccines
AIDS-Related Complex
AIDS Vaccines
Salk HIV Immunogen

Additional relevant MeSH terms:
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Freund's Adjuvant
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017